Common Contracts
3 similar Standstill and Stock Restriction Agreement contracts by Arcellx, Inc., Denali Therapeutics Inc.
ARCELLX, INC. AMENDED AND RESTATED STANDSTILL AND STOCK RESTRICTION AGREEMENTStandstill and Stock Restriction Agreement • February 28th, 2024 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Standstill and Stock Restriction Agreement (this “Agreement”) is being entered into as of November 15, 2023 (“Effective Date”) by and among Arcellx, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, Inc., a Delaware corporation (the “Investor”), which amends and restates that certain Standstill and Stock Restriction Agreement (the “Original Standstill Agreement”), dated December 8, 2022.
ARCELLX, INC. STANDSTILL AND STOCK RESTRICTION AGREEMENTStandstill and Stock Restriction Agreement • March 29th, 2023 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Standstill and Stock Restriction Agreement (this “Agreement”) is made as of December 8, 2022 (“Effective Date”) by and among Arcellx, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, Inc., a Delaware corporation (the “Investor”).
DENALI THERAPEUTICS INC. STANDSTILL AND STOCK RESTRICTION AGREEMENTStandstill and Stock Restriction Agreement • November 5th, 2020 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
This Standstill and Stock Restriction Agreement (this “Agreement”) is made as of September 22, 2020 (“Effective Date”) by and among Denali Therapeutics Inc., a Delaware corporation (the “Company”) and Biogen MA Inc., a Massachusetts corporation (the “Investor”).
